I don't have a forecasting tool that projects future TRx volume — the tools available compute KPIs from historical/current data (`kpi_calculate_tool`, `e2i_data_query_tool`) or model validated *causal* relationships (`causal_analysis_tool`); there is no predictive/time-series forecasting model exposed for volume KPIs in this toolset (the `predictions` query type and `prediction_synthesizer` agent exist in the architecture, but I don't have a callable forecast-generation tool here for TRx specifically). I won't fabricate a two-quarter projection.

What I *can* do that's adjacent and useful:

## No Forecasting Tool Was Run — Here's the Honest Answer

There's no forecasting/prediction tool in this system that projects Kisqali TRx volume forward two quarters — `predict_hcp_segment_likelihood_tool` scores HCP segment adoption propensity (and even that failed closed for Kisqali earlier), not volume trajectories. I won't fabricate a two-quarter forecast number. Here's the nearest real data I *can* give you, plus the biggest identified risk.

### Current TRx Level (Kisqali, last 6 months: Feb 18 – Aug 18, 2026)
**14,609 TRx**, computed from `treatment_events`.

⚠️ **Coverage warning (quoted from the tool):** *"66% of this 181-day total falls in its most recent 30 days — the data is not evenly distributed across the window. Do NOT treat the full-window figure as a baseline for the recent period; compare against a prior non-overlapping window instead."* I don't have a prior non-overlapping window to compare against, so I can't characterize a trend direction from this figure — only report the level and flag the concentration.

### Regional Monthly TRx vs. Target (from drift/gap reports, monthly grain — each row its own period)

| Region | Period (monthly grain) | TRx Value | Target | Achievement | YoY |
|---|---|---|---|---|---|
| Northeast | July 2026 | 252,475.15 | 269,839.25 | 93.6% | +28.3% |
| Northeast | August 2026 | 207,270.27 | 280,308.15 | **73.9%** | +22.0% |
| South | July 2026 | 203,507.59 | 215,586.21 | 94.4% | +30.0% |
| South | August 2026 | 238,448.55 | 221,514.66 | 107.6% | +24.3% |
| West | August 2026 | 197,408.46 | 233,893.72 | 84.4% | +24.5% |

*(No West or July-South business_metrics figure carrying the same substrate is available for a fifth row beyond what's shown; these are `business_metrics`-substrate figures, not comparable to the `treatment_events`-substrate 14,609 total above per the scale guard — different quantities, kept in separate rows.)*

### Biggest Risk to Any Forward Projection

Two converging signals point to the same risk:

1. **Northeast's achievement dropped from 93.6% (July) to 73.9% (August)** — the largest target miss of any region/period shown, despite still-positive YoY growth (+22.0%). If that gap widens rather than closes, it's the clearest drag on any two-quarter volume projection.
2. **Competitor activity is the only validated *negative* causal driver on Kisqali TRx market share**: effect size **-0.073**, confidence 0.793, business impact **-$24,218.40** (via `share_of_voice`, 70-day lag). This is a structural headwind independent of any single region's monthly miss.

**Bottom line:** I can't give you a numeric two-quarter forecast, but the risk most likely to erode whatever trajectory Kisqali is on is **competitor share-of-voice pressure compounding with Northeast's slipping target achievement** — worth monitoring both before committing to a specific volume number next quarter.